Stocks on Tech Trader

Summary: Price is holding steady just above our entry at 336.29 with no major breakdown on the daily chart, and recent positive developments like the $300M manufacturing expansion plus raised 2026 guidance support continued upside over the next week or more. The stock has stabilized after the post-earnings dip, showing resilience around current levels without clear reversal signals, so staying in the long position aligns with our goal of capturing larger moves while avoiding whipsaw trades. Fundamentals remain constructive with strong pipeline momentum and analyst support still leaning positive despite minor target tweaks.

Summary: Recent earnings beat with raised 2026 guidance and pipeline progress like MariTide give AMGN solid upside potential from current levels around 335. ...

Summary: Recent earnings beat with raised 2026 guidance and pipeline progress like MariTide give AMGN solid upside potential from current levels around 335. ...

Summary: Price action has been choppy and range-bound since the post-earnings drop, with no clear breakout or sustained momentum to justify a new position. ...

Summary: Recent consolidation around 330 after a post-earnings drop and repeated losing trades signals high risk of whipsaws, so staying out preserves capital until a clear breakout emerges. ...

Summary: AMGN is consolidating near 328 after the sharp post-earnings drop with mixed analyst views and no clear bullish reversal yet. ...

Summary: Price action shows a weak post-earnings bounce after the sharp May 1 drop, with low volume and no strong follow-through above key resistance around 340. ...

Summary: AMGN dropped sharply after its Q1 beat and guidance, landing in a choppy zone around 324-328 with no strong reversal signal yet, so cash keeps us out of the whipsaw risk....

Summary: AMGN just crashed hard post-earnings on fresh FDA withdrawal risk for Tavneos plus IRS tax exposure, breaking key support with no reversal signs yet. ...

Summary: ...

Summary: The FDA's proposal to withdraw Tavneos approval over data manipulation claims and serious liver injury risks has triggered a sharp selloff that overshadows the solid Q1 earnings beat, leaving no high-confidence setup for a multi-day hold. ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: We're staying in CASH for AMGN right now as of 4/7/26 at ~$340 after four consecutive losing long trades, with the stock in a clear daily downtrend off $388 highs, below key moving averages, and showing strong sell technical signals. ...

Summary: AMGN is in a steady downtrend since early March with lower highs and lower lows, plus our last four long trades all lost money, so we're staying in cash until the price action improves. ...

Summary: Exiting our long from 351.85 on 3/31/26 at current ~347.50 levels as AMGN breaks lower with price well below EMAs, bearish MACD, RSI 39, and oversold stoch failing to hold support. ...

Summary: AMGN pushed higher today reaching 357 before closing up with decent volume, showing continued strength, so we remain long the position from yesterday at $351.85....

Summary: AMGN recovered from new lows near 347 to close higher on solid volume with no major negative developments, so we remain long the position entered four days ago at $349.77....

Summary: Although we went long four days ago on signs of rebound and positive pipeline news, the lack of follow-through with repeated failures to hold gains means those reasons no longer apply so we're moving to cash....

Summary: We went long four days ago on signs of rebound and exhausted selling but are now exiting to cash because today's open-to-close reversal on higher volume shows buyers have stepped away and the setup no longer holds....

Summary: AMGN is consolidating quietly above our entry on persistently low volume with no negative news, so we're staying long the position from three days ago at $349.77....

Summary: AMGN pushed higher today to close at 353.34 on very low volume with no negative news or selling pressure, so we're staying long the position from two days ago at $349.77....

Summary: ...

Summary: We stayed in cash after the recent breakdown but are now going long because this rebound off the lows on lighter volume shows selling has dried up while the longer-term uptrend and pipeline news remain supportive. ...

Summary: AMGN keeps making new lows on rising volume with no technical reversal in sight, so we remain in cash after our recent exit. ...

Summary: We're staying in cash as AMGN's short-term downtrend continues without a clear reversal signal after the breakdown that prompted our exit. ...

Summary: Although we went long two days ago expecting the pullback to hold support near $360 in the uptrend, today's break to new lows at 350.81 on higher volume changes that so we're exiting to cash now. ...

Summary: We're staying long from our entry near $366.25 yesterday as AMGN is holding in a healthy pullback within its larger 2025-2026 uptrend despite today's lower close. ...

Summary: AMGN is in a clear long-term uptrend after its 2025 recovery and February 2026 rally, with the current pullback to the $366 area holding key support on declining volume. ...

Summary: Exiting LONG on AMGN at 366.87 after 4-bar hold amid continued downside breach of key supports like 370 with bearish MACD crossover, declining STO to oversold, neutral RSI, low volume, and no immediate bullish catalysts overriding broader market weakness; next earnings May 7, 2026, with potential Leerink conference in April....

Summary: Holding LONG on AMGN despite dip to 370.21 amid low volume and bearish MACD crossover, as uptrend holds above supports with bullish MariTide Phase 3 progress, strong osteoporosis sales, positive 2026 revenue outlook of $37-38.4B, Wells Fargo PT at $375, completed biosimilar trial, and Q2 dividend; next earnings May 7, 2026, with Leerink conference potential....

Summary: Holding LONG on AMGN as price holds steady at 375.72 with MACD showing easing bearishness, positive 2026 revenue guidance of $37-38.4B, Wells Fargo PT raise to $375, completed Phase 3 biosimilar trial, and Q2 dividend; next earnings May 7, 2026, with potential Leerink conference catalysts....

Summary: Holding LONG on AMGN as price stabilizes at 376.8 amid easing MACD bearishness, Goldman $415 PT raise, Q2 dividend announcement, and overlooked R&D reassess; next earnings May 7, 2026, with Leerink conference insights potentially positive....

Summary: Re-entering LONG on AMGN after swift recovery to 376.72 from 3/5 exit at 367.6, as market overlooks R&D reassess news with strong 2026 guidance, undervalued status, and uptrend support; prior bearish MACD easing, next earnings ~May 1, 2026....

Summary: Staying in cash as price stabilizes near recent lows with persistent bearish MACD crossover and no strong reversal signal overriding yesterday's exit reasons, despite positive Q4 earnings beat and guidance....

Summary: Sharp 4% intraday drop to 363.74 amid broader market sell-off, bearish MACD crossover with line below signal, STO declining to 47 from highs, RSI at neutral 47, and recent insider selling by EVP of 54k shares indicate weakening momentum in prior uptrend; exit LONG to CASH locking in 10% gains from 330.11 entry....

Summary: Strong uptrend persists with recent hammer reversal, positive MACD momentum despite minor pullback, RSI at sustainable 58, high STO, and bullish catalysts from Q4 earnings beat plus robust 2026 guidance outweighing biosimilar pressures; hold LONG for continued gains....

Summary: Strong uptrend continues with positive MACD, sustainable RSI 58, high STO momentum, hammer candle signaling reversal, and bullish oncology catalysts like MariTide Phase 3 outweighing biosimilar erosion; hold LONG for further upside....

Summary: Strong uptrend persists with bullish MACD crossover, RSI at sustainable 63, high STO momentum, and positive oncology pipeline news outweighing biosimilar pressures; hold LONG for continued gains....

Summary: Strong uptrend continues with bullish MACD, elevated but sustainable RSI, recent drug approvals and upward earnings revisions outweighing insider sale; hold LONG for further momentum....

Summary: Continuing strong uptrend with all-time highs post-earnings beat, positive MACD, bullish options activity, and no immediate catalysts to reverse; hold LONG for further gains....

Summary: Sustained bullish momentum with price breaking to new highs above key supports, positive MACD divergence, recent earnings beat and upbeat FY26 guidance fueling optimism despite mixed analyst targets....

Summary: Sustained uptrend with price above key EMAs, bullish MACD crossover holding strong, recent Piper Sandler PT raise to $432 on pipeline momentum, and unusual call options volume indicating trader optimism for further gains....

Summary: Sustained bullish momentum with price above key supports, positive MACD crossover, and recent Piper Sandler PT raise to $432 signaling strong pipeline potential despite mixed analyst views, holding above $360 for further upside to $400+....

Summary: Sustained uptrend post-earnings surge with bullish Piper Sandler $432 PT raise, strong Q4 beat and FY2026 guidance, unusual call options volume signal continued momentum above $360 support despite minor pullback, targeting $400+....

Summary: Sustained uptrend post-earnings surge, bullish analyst upgrades including Piper Sandler's $432 PT raise, unusual call options volume, and potential obesity acquisition signal strong momentum above $360 support, targeting $400+....

Summary: Sustained uptrend post-Q4 earnings beat, positive 2026 guidance, UPLIZNA EU approval, analyst upgrades, and dividend increase reinforce bullish momentum above $360 support, targeting $390+....

Summary: Post-Q4 beat + 2026 guide beat + UPLIZNA EU approval sustain uptrend; price ~$373 above $360 support eyes $390+....

Summary: AMGN's strong uptrend persists with price above key EMAs, positive MACD, and recovery from pullback, supported by recent earnings beat and oncology pipeline momentum despite biosimilar pressures....

Summary: Q4 earnings crush + 2026 guide beat + dividend ex-tomorrow hold momentum above $360 support despite -3% dip....

Summary: Q4 beat momentum + Zacks top-ranked + Strong Buy techs hold firm post -3% dip; dividend ex 2/13 dip-buy opportunity....

Summary: Post-Q4 beat + 2026 guide $37-38.4B rev/$21.6-23 EPS + Argus $400 PT propel new highs ~$364 amid MariTide oncology catalysts....

Summary: Strong Q4 earnings beat, upbeat 2026 guidance, and MariTide pipeline excitement sustain the bullish uptrend with new highs....

Summary: Strong bullish momentum from Q4 earnings beat, raised analyst targets, and optimistic 2026 revenue guidance propel the stock to new 52-week highs amid a clear uptrend....

Summary: Q4 earnings beat ($5.29 EPS vs $4.76 est, $9.9B rev +9%) + 2026 EPS guide $21.60-23 propel new 52-wk highs ~$375....

Summary: UBS $390/ Oppenheimer $400 PT hikes + bull flag breakout into Feb3 earnings trump eczema drug termination refocus....

Summary: Zacks momentum stock + Piper $381 PT amid new 52-wk highs/ATH breakout on MariTide strength....

Summary: Stock +1% to $347 outpaces market (Nasdaq 1 day ago); Seeking Alpha Buy on MariTide (1 day ago) + Ro collab trump Bernstein $335 cut (18hrs ago)....

Summary: Seeking Alpha Buy thesis on MariTide obesity/T2D upside (4hrs ago) + Ro collab reinforces 2026 springboard over Bernstein $335 PT....

Summary: Ro obesity collab + MariTide Phase 3 push/Dark Blue/DISCO oncology deals outweigh Bernstein $335 downgrade; 2026 springboard intact....

Summary: 2026 "springboard year" via MariTide Phase 3 push + Dark Blue/DISCO oncology deals; UBS/Piper/JPM/HSBC PTs avg $380+....

Summary: MariTide Phase II extension maintains weight loss (Reuters 4 days ago); Dark Blue $840M + DISCO oncology deals + 26% YTD attractiveness signal more upside....

Summary: MariTide extension data shows sustained weight loss (Reuters 3 days ago) + Dark Blue/DISCO oncology deals cement 2026 "springboard year."...

Summary: UBS strong-buy upgrade + Dark Blue $840M/DISCO $618M oncology deals signal pipeline acceleration past biosimilars noise....

Summary: DISCO oncology deal (up to $618M) + UBS Buy/Dark Blue $840M reinforce pipeline strength over biosimilars pressure....

Summary: UBS Buy reiteration + Dark Blue $840M/DISCO oncology deals fuel upside past biosimilars hit; momentum intact....

Summary: UBS Buy reiteration + $840M Dark Blue oncology acquisition propel stock higher, offsetting biosimilars FDA nod....

Summary: Dark Blue $840M acquisition + UBS buy call drive stock jump despite biosimilars; prior SHORT rev erosion thesis overridden by oncology pipeline boost—flip after 9 days as market shrugs FDA nod....

Summary: Dark Blue $840M oncology buy (1 day ago) cushions pipeline but Amneal biosimilars FDA nod (1 day ago) still erodes $5.3B Prolia/Xgeva revs....

Summary: Amneal denosumab biosimilars FDA-approved (9hrs ago), stock at 52-wk high $13.04; Prolia/Xgeva $5B+ rev erosion trumps oncology M&A....

Summary: Fresh FDA approvals for Amneal denosumab biosimilars (5hrs ago) hit Prolia/Xgeva $5.3B rev hard; bearish wedge/RSI div targets $280....

Summary: Amneal/mAbxience denosumab biosimilars FDA-approved (latest nod 7hrs ago); Prolia/Xgeva rev erosion + Seeking Alpha 2026 rally doubts persist....

Summary: Year-end thin vol + biosimilars LOE unwind (Prolia/Xgeva $5B rev risk); RSI bear div targets $290-300....

Summary: Amneal denosumab biosimilars FDA-approved Dec22 erode ~$5B Prolia/Xgeva revs; Seeking Alpha flags 2026 rally risks....

Summary: Biosimilars FDA approval hits Prolia/Xgeva (~$5B rev risk); Amneal surge + technical wedge failure target $310-320....

Summary: AMGN continues in a strong uptrend with price above rising EMA and SMA, holding above recent support around 320 after December dip, positive momentum from MACD and RSI, no imminent earnings or bearish news, targeting resistance near 345 while watching for sustained breaks below 325....

Summary: AMGN remains in a solid uptrend with price above rising EMA and SMA, positive MACD, recent support at 313-320 holding after December pullback, no imminent earnings or bearish catalysts, targeting resistance near 345 while monitoring for breakdowns below 325....

Summary: AMGN continues its uptrend with price above rising EMA and SMA, positive MACD, recent bounce from 313-315 support holding firm, no bearish catalysts or earnings imminent, targeting resistance near 345 while watching for breakdowns below 320....

Summary: AMGN remains in a strong uptrend with price above rising EMA and SMA, positive MACD momentum building after recent bounce from 313-315 support, no immediate earnings or bearish catalysts, holding the long position targeting resistance near 345 while monitoring for breakdowns below 320....

Summary: AMGN continues in a strong uptrend with price above rising EMA and SMA after bouncing from 313-315 support, positive MACD momentum, and no immediate bearish catalysts or earnings, holding the long position targeting resistance near 345 while monitoring for breakdowns below 320....

Summary: AMGN remains in a recovering uptrend after bouncing from key support at 313-315, with price above rising SMA despite a minor pullback below EMA, positive though weakening MACD, and no immediate earnings or bearish catalysts, holding the long position targeting resistance near 345 while monitoring for sustained weakness below 320....

Summary: AMGN continues in a strong uptrend with price above rising EMA and SMA, recent support at 313-315 holding after a bounce, positive MACD momentum persisting, and no immediate earnings or bearish catalysts, targeting resistance near 345 while avoiding premature exit....

Summary: AMGN remains in a clear uptrend with price above rising EMA and SMA, recent bounce from 313-315 support holding firm, positive momentum from MACD and no near-term earnings or catalysts, targeting resistance near 345 while monitoring for pullbacks without exiting prematurely....

Summary: AMGN is in a clear uptrend with price above rising EMA and SMA after bouncing from recent lows around 313-315 support, supported by positive momentum indicators and no immediate earnings risk, justifying a long entry on this dip with targets near prior highs around 345....

Summary: AMGN's trend is unclear with price below EMA despite being above SMA, recent sharp pullback from 345 highs without volume capitulation, and history of losses on premature long entries during similar declines warrant staying in cash for a better setup....

Summary: AMGN has pulled back sharply from 345 highs to around 316 near potential support, with price below declining EMA amid weakening momentum and no fresh bullish news on MariTide or other pipelines, prompting exit of the long position after 11 bars to avoid further downside risk....

Summary: AMGN remains in a broader uptrend with price pulling back to potential support around 315 after a strong run-up to 345 on positive MariTide obesity drug developments, supported by solid fundamentals like revenue growth and no imminent earnings or negative catalysts, justifying holding the existing long position despite the current drawdown....

Summary: AMGN continues in an uptrend with EMA above SMA and both rising, price pulling back from 345 highs to 321 near rising support around 320-330, supported by positive MariTide phase 3 obesity drug data and strong fundamentals like revenue growth, no near-term earnings or catalysts, justifying holding the long position entered at 334.3 despite current drawdown....

Summary: AMGN remains in a solid uptrend with price above rising EMA and SMA, recent pullback to support near 330 after highs at 345, supported by positive MariTide obesity drug developments and no immediate earnings or catalysts, justifying holding the long position from 334.3 despite minor drawdown....

Summary: AMGN continues in a strong uptrend with price above rising EMA and SMA, recent consolidation near 340 after breakout supported by positive MariTide phase 3 data and no near-term earnings, justifying holding the long position from 334.3 for further upside potential....

Summary: AMGN remains in a strong uptrend with price above rising EMA and SMA, recent breakout above prior resistance around 345 supported by positive MariTide developments and no immediate earnings risk, justifying holding the long position entered at 334.3 for further potential upside....

Summary: AMGN's uptrend persists with price above rising EMA and SMA, recent pullback from 345 resistance finding support above 334 entry, bolstered by positive MariTide Phase 3 data and no near-term earnings risk, justifying holding the long position for further upside....

Summary: AMGN remains in a strong uptrend with price above rising EMA and SMA, recent closes pushing toward 345 resistance amid positive MariTide momentum and no immediate catalysts, supporting holding the long position from 334.3 for further potential gains....

Summary: AMGN continues in a robust uptrend with price above rising EMA and SMA, approaching resistance near 345 but with strong momentum from positive MariTide Phase 2 data and no near-term catalysts, justifying holding the long position entered at 334.3 for potential further upside....

Summary: AMGN remains in a strong uptrend with price above rising EMA and SMA, recent pullback bought as a dip post-earnings breakout with positive momentum indicators like bullish MACD and high RSI, supported by favorable pipeline updates on MariTide and no immediate catalysts or earnings within 3 days....

Summary: AMGN is in a clear uptrend with price above rising EMA and SMA, recent pullback from highs offering a dip-buy opportunity post-earnings breakout, supported by positive pipeline news and no near-term catalysts. ...

Summary: AMGN has reached near the $350 resistance level in a strong uptrend following positive earnings and MariTide developments, but with price stalling at recent highs and no new catalysts, exiting the long position locks in profits after the minimum hold period....

Summary: AMGN continues its strong uptrend with price above rising EMA and SMA, recent breakout on positive earnings and MariTide momentum pushing toward $350 resistance, supported by bullish MACD and no immediate catalysts for reversal....

Summary: AMGN maintains a robust uptrend with price well above rising EMA and SMA, recent earnings beat fueling a high-volume breakout to new 52-week highs around $345, supported by bullish MACD crossover and positive pipeline developments like MariTide obesity drug progress, targeting resistance near $350-360 while avoiding overbought exits....

Summary: AMGN continues strong uptrend with price above rising EMA/SMA, recent earnings beat driving breakout to new highs on high volume, bullish MACD divergence, and positive pipeline news supporting further upside to $350+ resistance despite no volume capitulation....

Summary: AMGN remains in a strong uptrend with price above rising EMA and SMA, recent post-earnings breakout to new highs on high volume, supported by bullish MACD and no immediate catalysts, holding for further upside toward $350+ targets....

Summary: AMGN's strong uptrend continues with price breaking above $329 resistance to new highs near $338 on high volume post-earnings, supported by bullish MACD and positive pipeline developments, holding for targets around $340-350 while minimum period unmet....

Summary: AMGN remains in a strong uptrend with price breaking to new highs above $329 resistance on high volume after a positive earnings reaction, supported by bullish MACD crossover and positive pipeline news, targeting $340-350 while holding through the minimum period....

Summary: AMGN's strong uptrend persists with price breaking to new highs above $329 resistance on high volume post-earnings beat, bullish MACD and positive pipeline developments supporting further upside toward $340-350....

Summary: AMGN continues strong uptrend with price breaking above prior highs post-earnings beat, supported by bullish MACD crossover and high volume, targeting resistance near $329 amid positive drug pipeline news....

Summary: AMGN remains in a strong uptrend with price above rising EMA and SMA, recent earnings beat driving a breakout above $310 resistance, bullish MACD and high volume supporting continued upside toward $329....

Summary: AMGN is in a clear uptrend with price above rising EMA and SMA, recent positive earnings reaction on 11/5/2025 driving a breakout above prior resistance, and bullish MACD crossover supporting a long entry on this pullback to around 315 with targets near 329....

Summary: AMGN's strong post-earnings jump on 11/5/2025 pushed price to overbought highs near resistance without a dip in the clear uptrend, so staying in cash avoids poor entry with unfavorable risk/reward while awaiting a pullback for high-confidence long setup....

Summary: AMGN's chart shows an uptrend with EMA above SMA and both rising, but earnings today prevent entry despite positive pipeline news and no shorting allowed for biotech stocks....

Summary: AMGN's chart shows a clear uptrend with price above rising EMA and SMA, but upcoming earnings on 11/4/2025 block any new entry today, and as a biotech stock, shorting is off-limits, so staying in cash avoids risk while waiting for post-earnings clarity....

Summary: AMGN's chart shows a potential uptrend with price above EMA and SMA, but upcoming earnings on 11/4/2025 warrant staying in cash to avoid volatility, especially after recent exit on 10/24/2025 due to weakening momentum and no strong bullish catalysts outweighing the risk....

Summary: AMGN's technicals show an unclear trend with EMA slightly above SMA but price below EMA, both moving sideways in a tight range without clear direction or volume capitulation, making new entries inadvisable while recent trade history indicates repeated losses on longs in similar setups....

Summary: Staying in cash as the chart shows sideways churning with MACD bearish crossover, no clear uptrend momentum after recent exit on weakening signals, and upcoming earnings adding risk without meeting hold-through criteria....

Summary: Staying in cash due to unclear trend with price below EMA, no volume capitulation, recent exit on weakening signals, and earnings tomorrow on 10/29/2025 risking volatility. Price has crossed the EMA multiple times recently (e.g., below on 10/24, above on 10/15), indicating unclear direction and potential whipsaw risk—similar to past setups in August-September 2025 where entries in choppy ranges led to quick losses, as seen in our trade history with repeated small losses from failed bounces....

Summary: AMGN's trend is unclear with EMA slightly above SMA but both trending sideways, price below EMA without volume capitulation, and earnings on 10/29/2025 imminent, warranting cash to avoid risk....

Summary: Exiting the long position in AMGN as price has fallen below the EMA with a bearish MACD crossover, indicating weakening momentum after failing to hold above recent resistance at 302.33, compounded by no volume capitulation and upcoming earnings risk on 11/4/2025....

Summary: Holding the existing long position in AMGN as the uptrend remains intact with price above both EMA and SMA, recent pullback from 303 high seen as a healthy dip near 302.33 resistance, bolstered by positive pipeline updates and no pressing bearish factors ahead of earnings on 10/29/2025....

Summary: AMGN's uptrend persists with price above EMA and SMA, recent highs near resistance at 302.33 suggesting potential for further upside before earnings on 10/29/2025, supported by positive pipeline news and no immediate bearish catalysts warranting early exit....

Summary: AMGN remains in a strong uptrend with price above EMA and SMA, recent breakout above $298 on positive volume, supportive MACD crossover, and bullish news on pipeline advancements outweighing the upcoming earnings risk on 10/29/2025....

Summary: AMGN maintains a clear uptrend with price above EMA and SMA, positive MACD divergence, recent breakout above $302 resistance on increased volume, and the position held only 4 bars amid supportive biotech sector momentum outweighing distant earnings risks....

Summary: AMGN remains in a clear uptrend with price above both EMA and SMA, positive MACD momentum, recent bounce from support, and the position has only been held for 3 bars, far short of the minimum multi-week hold, outweighing any near-term concerns ahead of earnings on 10/29/2025....

Summary: AMGN maintains an uptrend with price above EMA and SMA, recent MACD bullish crossover, bounce from support near 290, and positive pipeline momentum without immediate exit triggers after only 2 bars held....

Summary: AMGN remains in a clear uptrend with price above both EMA and SMA, recent positive momentum from MACD and bounce off support near 290, supported by bullish pipeline news and no immediate catalysts warranting exit after just 1 bar....

Summary: AMGN is in a clear uptrend with price above both EMA and SMA, recent bounce from support around 290 showing strength, positive MACD crossover, and bullish news on pipeline advancements supporting upside potential over the next few weeks before earnings....

Summary: AMGN's current uptrend shows promise with price above EMA and SMA, but overbought indicators, proximity to resistance at 302, and upcoming earnings on 10/29/2025 without strong historical surprises suggest waiting for a clearer dip or catalyst for entry....

Summary: AMGN's technicals show an unclear trend with EMA and SMA tightly rangebound without volume capitulation, advising against new entries despite price above both, while next earnings are on 10/29/2025 with no other immediate catalysts found. Historical simulations reveal similar setups in August-September led to whipsaws, with price oscillating without sustained moves, and past trades like the August long entry resulted in a loss due to trend reversal, reinforcing caution. No volume capitulation flags in the data, and support levels at 267-270 could hold if tested, but resistance around 300-302 has capped upside recently. Fundamentally, Amgen's strong pipeline in oncology and biosimilars provides long-term bullishness, but recent news searches yield neutral items like routine FDA approvals with no major catalysts imminent—e.g., a bullish mention of obesity drug progress classified as bullish (credible from company filings, timely, potential for positive reaction if trials advance), yet not material enough to override technical hesitation. Unusual options activity shows elevated calls, but volume isn't extreme, and insider buys are absent. Broader market factors like rising interest rates could pressure biotech valuations, though AMGN's dividend yield offers some buffer.

Summary: Staying in cash as the trend is unclear with EMA and SMA tightly rangebound without clear separation or volume capitulation, avoiding new entries per technical guidelines despite recent price bounce and uptrend signals....

Summary: AMGN's trend is unclear with EMA slightly below SMA despite price above both, avoiding new long entries per technical rules, while being a biotech stock prohibits shorting, and no volume capitulation or overriding catalysts justify deviation....

Summary: AMGN's trend is unclear with EMA below SMA but price above both, no volume capitulation, and recent crossings indicate ranging without clear direction, so avoid new entries while biotech nature precludes shorting....

Summary: Staying in cash as AMGN's trend is unclear with EMA below SMA despite price above both, no volume capitulation for a long entry in potential downtrend, and it's a biotech stock unsuitable for shorting, while recent price action shows consolidation without high-confidence setup for a multi-week hold. This setup advises against new entries, especially since we're aiming for holds of at least 10-14 days and avoiding poor entries like buying near range tops. Key support sits at $267.15 (strong with 9 bounces) and $253.3, while resistance is at $302.33 and higher at $319.31/$329.17; current price is midway in a broader range from mid-2025 lows around $260s to highs near $300s, suggesting potential for whipsaw without clear direction....

Summary: AMGN's trend is unclear with EMA below SMA despite price above both, no volume capitulation, and recent history of losses from premature entries, so staying in cash avoids low-confidence setups while awaiting clearer uptrend signals or catalysts....

Summary: Staying in cash due to unclear trend with EMA below SMA, price above both but frequent crossings in past month without volume capitulation, avoiding new entries while monitoring for clearer uptrend signals amid recent volatility and no immediate catalysts....

Summary: AMGN's trend is unclear with EMA below SMA despite the recent breakout above both on high volume, lacking a clear uptrend for long entry and no volume capitulation to justify buying in potential downtrend, while biotech nature prohibits shorting....

Summary: Staying in cash as the trend remains unclear with EMA below SMA but price slightly above EMA, no volume capitulation for a long entry in this potential downtrend, and shorting is avoided for biotech stocks like AMGN due to high risk of sudden positive news spikes....

Summary: AMGN remains in a clear downtrend with EMA below SMA and price below both, no volume capitulation to signal a reversal, and as a biotech stock, shorting is avoided despite the technical setup, while fundamentals like stable drug pipeline don't override the weak chart for a long entry....

Summary: AMGN remains in a clear downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, and as a biotech stock, shorting is avoided despite the setup....

Summary: AMGN remains in a clear downtrend with price below both EMA and SMA, no volume capitulation to signal a bottom, and recent news lacks strong bullish catalysts, warranting caution and staying in cash for a better entry....

Summary: AMGN remains in a clear downtrend with price below both EMA and SMA, no volume capitulation for a long entry, and as a biotech stock, shorting is avoided despite bearish signals like the engulfing candle....

Summary: AMGN's trend is unclear with EMA below SMA and price between them, no recent volume capitulation to signal a bottom, and recent trade history shows losses from entering prematurely in downtrends, so staying in cash avoids low-confidence setups while awaiting clearer uptrend signals or catalysts....

Summary: AMGN's trend is unclear with EMA below SMA and price between them without volume capitulation, preventing new long entry, while its biotech nature rules out shorting, so staying in cash for better opportunities. Over the past month, EMA and SMA have not crossed frequently but remain somewhat tightly bound with price oscillating around them without decisive breaks, reinforcing the unclear trend. No volume capitulation flagged in the recent data, so no basis for buying a dip in this potential downtrend....

Summary: AMGN's trend is unclear with EMA below SMA and price between them without volume capitulation, so staying in cash to avoid low-confidence entries despite a recent bounce from support....

Summary: AMGN remains in a clear downtrend with EMA below SMA and price below both, lacking volume capitulation for a long entry, while shorting is avoided due to its biotech nature prone to sudden positive news spikes....

Summary: The chart indicates a downtrend with price below both EMA and SMA without recent volume capitulation, preventing a long entry, and shorting biotech stocks like AMGN is avoided due to potential sudden upside from news....

Summary: AMGN remains in a clear downtrend with EMA below SMA and price below both, no volume capitulation to signal a reversal, and as a biotech stock it can't be shorted despite bearish technicals, so staying in cash avoids poor entries while awaiting a high-confidence setup....

Summary: AMGN is in a clear downtrend with price below both EMA and SMA, no volume capitulation to signal a reversal, and as a biotech stock, shorting is avoided despite bearish momentum, so staying in cash until a better setup emerges....

Summary: AMGN remains in a clear downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, and as a biotech stock, shorting is avoided despite technical setup....

Summary: Downtrend confirmed with EMA below SMA and price below both, no volume capitulation for long entry, and as a biotech stock, shorting is avoided due to potential sudden news-driven spikes....

Summary: AMGN remains in a downtrend with EMA below SMA and price below both, no volume capitulation to justify a long entry, and as a biotech stock, shorting is avoided despite bearish technicals....

Summary: AMGN remains in a downtrend with price below both EMA and SMA, no volume capitulation for a long entry, and as a biotech stock, shorting is avoided due to sudden news risk, so staying in cash until a clearer uptrend or capitulation signal emerges....

Summary: AMGN is in a clear downtrend with price below both EMA and SMA, no volume capitulation for a long entry, and as a biotech stock it can't be shorted despite the technical setup favoring caution....

Summary: AMGN is in a clear downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, and as a biotech stock it cannot be shorted due to high risk of sudden positive news spikes....

Summary: AMGN is in a downtrend with EMA below SMA and price below both, but MAs are tightly rangebound without volume capitulation, making the trend unclear and unsuitable for new entries, while its biotech nature prohibits shorting despite bearish signals....

Summary: AMGN's chart shows a downtrend with price below both EMA and SMA, no volume capitulation for a long entry, and as a biotech stock, shorting is avoided due to potential sudden positive news....

Summary: Exiting the existing long position in AMGN as the minimum hold period has been met, with the trend now clearly down (EMA below SMA and price below both), no volume capitulation to signal a bottom, and price not near resistance for an optimal sell while lingering above weak support at 278.98 amid lack of strong bullish catalysts....

Summary: Holding existing long position in AMGN as the minimum hold period of 10-14 days hasn't been met yet, with price near support at 278.98 showing potential for rebound based on historical patterns despite current downtrend below EMA/SMA....

Summary: Holding existing long position in AMGN as the minimum hold period hasn't been met, with the downtrend showing price near support at 278.98 and historical rebounds in similar setups suggesting potential upside over weeks despite current pullback below EMA/SMA....

Summary: AMGN's chart indicates an unclear trend with tightly converged EMA and SMA around 293, price slightly below at 289.11 but above key support at 278.98, no volume capitulation or imminent catalysts warranting exit from the existing long position entered 7 bars ago at 296.47, with historical rebounds in similar pullbacks suggesting potential upside over weeks....

Summary: AMGN's chart shows a minor pullback to 287.94 below tightly converged EMA and SMA around 293, indicating unclear trend but no compelling exit signal from the existing long position entered at 296.47 six bars ago, with price above key supports like 278.98 and historical patterns suggesting potential rebounds without volume capitulation or imminent catalysts....

Summary: AMGN remains in a clear uptrend with price above both EMA and SMA, supporting holding the existing long position from 8/15 at $296.47 despite the minor pullback to $293.92 near support levels around $287-289, with no earnings or catalysts in the next 3 days and potential for rebound based on recent bounces from similar dips....

Summary: AMGN continues in an uptrend with price above EMA and SMA, no unclear trend signals, and the existing long position from 8/15 at $296.47 requires holding longer than 4 bars despite a slight dip to $295.43 near support....

Summary: AMGN remains in an uptrend with price above both EMA and SMA, no unclear trend signals, and the position is only 3 bars old requiring a longer hold despite minor fluctuations near support levels. ...

Summary: AMGN continues in an uptrend with price above EMA and SMA, no unclear trend signals or volume capitulation, and the position is only 2 bars old requiring longer hold despite recent minor dip near support....

Summary: AMGN remains in a mild uptrend with price slightly above EMA and SMA, no trend crossings or volume capitulation, and the position is too new to exit per holding requirements, supporting continued long hold despite minor pullback....

Summary: AMGN is in an uptrend with price above both EMA and SMA, recent bounce from support around 285 showing strength, and positive historical earnings reactions support holding for potential upside over the next few weeks....

Summary: AMGN's trend is unclear with price below both EMA and SMA despite EMA slightly above SMA, no recent volume capitulation, and recent trade history shows losses from premature entries near earnings, so staying in cash for a clearer high-confidence setup....

Summary: AMGN's trend is unclear with EMA slightly above SMA but price below both, no volume capitulation, and being a biotech stock prevents shorting, so stay in cash awaiting a clearer setup....

Summary: Trend is unclear with EMA marginally above SMA but price below both, MAs tightly rangebound without clear direction or volume capitulation, so stay in cash to await a high-confidence setup....

Summary: AMGN's trend is unclear with price below both EMA and SMA despite EMA slightly above SMA, lacking a high-confidence uptrend for long entry and prohibiting shorts on biotech stocks....

Summary: AMGN's chart shows an unclear trend with price below both EMA and SMA despite EMA slightly above SMA, and no volume capitulation, advising to stay in cash while positive Q2 earnings and raised guidance suggest potential upside but technicals don't confirm an uptrend entry yet....

Summary: AMGN's price has dropped sharply post-earnings despite a strong Q2 beat and raised 2025 guidance, with the chart showing an unclear trend as price sits below both EMA and SMA, warranting staying in cash to avoid low-confidence setups....

Summary: AMGN's trend is unclear with price below both EMA and SMA despite EMA above SMA, and the sharp post-earnings drop on strong results without volume capitulation advises staying in cash to avoid low-confidence entries....

Summary: AMGN's clear uptrend with price above EMA and SMA is overshadowed by today's earnings report after close, warranting caution to avoid volatility as historical post-earnings reactions have been negative in most cases....

Summary: AMGN is in a clear uptrend with price above EMA and SMA, but earnings on August 5, 2025, carry historical risk of negative one-day returns, so staying in cash avoids potential volatility while waiting for a post-earnings dip to enter long....

Summary: AMGN is in an uptrend with price above EMA and SMA, but with earnings on August 5, 2025 just days away and recent history of volatility around reports including a prior EPS miss, staying in cash avoids unnecessary risk despite positive news on clinical studies....

Summary: AMGN's trend is unclear with price below EMA despite EMA above SMA, and upcoming earnings on August 5, 2025, introduce volatility risk without sufficiently solid technicals to justify holding through. Positive news like expected Q2 earnings beat and analyst price target hikes to $326 from UBS suggest potential upside, but mixed signals including a recent BofA Sell rating and our prior loss from entering a similar dip warrant caution. No major event catalysts beyond earnings in the next few weeks based on available info, so staying in cash allows waiting for post-earnings clarity or a confirmed uptrend with price reclaiming above both averages. Simulating past setups, similar pre-earnings dips in 2024 often led to whipsaws, with less than 50% win rate on longs held through reports without overwhelming positives, reinforcing the decision to avoid entry now and monitor for better opportunities in 10-14 days.

Summary: AMGN remains in a clear uptrend with price above EMA and SMA, but with earnings on August 5, 2025 approaching and recent history of exiting to mitigate risk amid mixed analyst views, staying in cash avoids potential volatility while waiting for a post-earnings entry....

Summary: AMGN is in a clear uptrend with price above both EMA and SMA, but upcoming earnings on August 5, 2025, pose high volatility risk amid mixed analyst views including a recent BofA Sell rating and last quarter's EPS miss, making it unwise to enter a new long position that would require holding through the event without compelling positive evidence....

Summary: AMGN's price has dipped below the entry point in this uptrend, and with earnings on August 5, 2025 approaching amid mixed analyst views including a recent BofA Sell rating, exiting the long position now mitigates risk while locking in the current status before potential volatility....

Summary: AMGN is in a clear uptrend with price above EMA and SMA, supported by positive analyst upgrades expecting an earnings beat on August 5, 2025, and recent news on successful Phase III COPD study, justifying a long entry on this dip with intent to hold through earnings given the favorable outlook....

Summary: AMGN remains in an uptrend with price above EMA and SMA, but upcoming earnings on August 5, 2025, pose significant risk given the last quarter's EPS miss and mixed analyst targets, warranting caution to avoid holding through the event....

Summary: AMGN's recent uptrend is strong with price above EMA and SMA, but upcoming earnings on August 5, 2025, combined with last quarter's EPS miss, warrants exiting the long position to mitigate risk despite positive analyst updates and news sentiment....

Summary: AMGN maintains a strong uptrend with EMA above SMA and price above both, supported by UBS's raised price target to $326 expecting a Q2 earnings beat, and positive updates on leukemia and gastric cancer trials, despite upcoming earnings....

Summary: AMGN remains in a clear uptrend with EMA above SMA and price above both, no trend invalidation, supported by recent positive phase 3 trial data for rocatinlimab and stable fundamentals ahead of August earnings, justifying holding the long position for at least 10-14 days....

Summary: AMGN's chart displays a strong uptrend from June lows with bullish MACD crossover and neutral RSI, bolstered by recent positive earnings reports and promising drug trial updates, suggesting upside potential over the coming weeks....